Detalhe da pesquisa
1.
Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652-3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer.
Clin Cancer Res
; 30(10): 2140-2159, 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38376926